Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced the primary endpoint was met in the Phase 3 portion of the AZURE-1 study evaluating brelovitug, an ...
NEAR holds near $4.40 after its Intents rally, while MemeToro’s public fair-launch code gives BNB Chain users a fresh early-entry opportunity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results